OHDSI MEETINGS THIS WEEK
OMOP CDM Oncology WG - Genomic Subgroup Meeting - Tuesday at 9am ET
OHDSI Community Call - Tuesday at 12pm ET
Oncology WG - Development Subgroup Meeting - Wednesday at 10am ET
OMOP CDM Oncology WG - CDM/Vocabulary Subgroup Meeting - Thursday at 10am ET
You can find a full list of upcoming OHDSI meetings here:
Favorite 2019 OHDSI Papers - We want to create a thread of the community’s favorite or most inspiring OHDSI papers from the past 12 months.Was there a paper that used OHDSI tools and standards particularly inspiring to you? Please share them here: Favorite OHDSI Papers Of 2019
Two OHDSI studies published in Lancet! Another OHDSI study has been published in Lancet! The EHDEN team’s Rheumatology paper is available here: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(19)30075-X/fulltext
If you haven’t yet checked out the LEGEND hypertension study in the Lancet, you can check it out here:
For more info on the study, check out our press release:
2019 OHDSI Symposium - Tutorial Videos Videos from the 2019 OHDSI tutorials are officially online! You can access tutorial videos and materials here:
I know it sounds weird, but how bad, how hard can dying be?
Cher COMMUNITY PUBLICATIONS
Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults.
M Beauchemin, L Sung, DL Hershman, C Weng, LL Dupuis and R Schnall,
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Jan 23 2020
Prescribing guideline-recommended anti-emetics is an effective strategy to prevent CINV. However, the rate of guideline-concordant care is not well-understood. The purpose of this study was to describe the proportion of pediatric, adolescent, and young adult patients receiving HEC or MEC who received guideline-concordant antiemetic prophylaxis for acute CINV and to identify potential predictors of guideline-concordant antiemetic prophylaxis.Using electronic health record data from 2016 through 2018, a retrospective single-institution cohort study was conducted to investigate how often patients less than 26 years of age receiving moderately or highly emetogenic chemotherapy receive guideline-concordant prophylaxis for acute CINV. Guideline-concordant care was defined according to guidelines from the Pediatric Oncology Group of Ontario for patients < 18 years and the American Society of Clinical Oncology for those ≥ 18 years. Independent variables included: sex, age, insurance status, race, ethnicity, cancer type, chemotherapy regimen, clinical setting, chemotherapy emetogenicity, and patient location. Predictors of receiving guideline-concordant care were determined using multiple logistic regression.Of 180 eligible patients, 65 (36.1%) received guideline-concordant care. In multivariable analysis, being treated in adult oncology setting (aOR 14.3, CI95 5.3-38.6), with a cisplatin-based regimen (aOR 3.5, CI951.4-9.0), solid tumor diagnosis (aOR 2.2, CI95 1.0-4.8), and commercial insurance (aOR 2.4, CI95 1.1-5.2) were associated with significantly higher likelihood of receiving guideline-concordant care.Multi-level factors were associated with receiving guideline concordant care for prevention of CINV in children, adolescents, and young adults receiving emetogenic chemotherapy. These findings can inform current efforts to optimize implementation strategies for supportive care guidelines.
Opioid prescriptions in patients with osteoarthritis: a population-based cohort study.
JJ van den Driest, D Schiphof, M de Wilde, PJE Bindels, J van der Lei and SMA Bierma-Zeinstra,
Rheumatology (Oxford, England), Jan 2020 20
To examine the incidence, prevalence and trends for opioid prescriptions in patients with OA. Furthermore, types of opioids prescribed and long-term prescription rates were examined. Finally, the patient characteristics associated with the prescription of opioids were assessed.A population-based cohort study was conducted using the Integrated Primary Care Information database. Incidence and prevalence of opioid prescriptions were calculated for the period 2008-2017. Logistic regression was used to assess which patient characteristics were associated with opioid prescriptions.In total, 157 904 OA patients were included. The overall prescription rate remained fairly stable, at around 100 incident and 170 prevalent prescriptions per 1000 person years. However, the incident prescription rate for oxycodone increased from 7.1 to 40.7 per 1000 person years and for fentanyl from 4.2 to 7.4 per 1000 person years. The incident prescription rate for paracetamol/codeine decreased from 63.0 to 13.3 per 1000 person years. Per follow-up year, long-term use was found in 3% of the patients with incident OA. Finally, factors associated with more prescriptions were increasing age, OA in ≥2 joint groups [odds ratio (OR) 1.56; 95% CI: 1.51, 1.65] and the presence of other musculoskeletal disorders (OR 4.91; 95% CI: 4.76, 5.05). Men were less likely to be prescribed opioids (OR 0.78; 95% CI: 0.76, 0.80).Prescription rates for opioids remained stable, but types of opioids prescribed changed. Oxycodone and fentanyl were increasingly prescribed, while prescriptions of paracetamol/codeine decreased. Since the benefit of opioids for OA pain is questionable and side effects are common, opioids should be prescribed with caution.
Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease.
D Klarin, E Busenkell, R Judy, J Lynch, M Levin, J Haessler, K Aragam, M Chaffin, M Haas, S Lindström, TL Assimes, J Huang, K Min Lee, Q Shao, JE Huffman, C Kabrhel, Y Huang, YV Sun, M Vujkovic, D Saleheen, DR Miller, P Reaven, S DuVall, WE Boden, S Pyarajan, AP Reiner, DA Trégouët, P Henke, C Kooperberg, JM Gaziano, J Concato, DJ Rader, K Cho, KM Chang, PWF Wilson, NL Smith, CJ O'Donnell, PS Tsao, S Kathiresan, A Obi, SM Damrauer and P Natarajan,
Nature genetics, 2019 11
Venous thromboembolism is a significant cause of mortality1, yet its genetic determinants are incompletely defined. We performed a discovery genome-wide association study in the Million Veteran Program and UK Biobank, with testing of approximately 13 million DNA sequence variants for association with venous thromboembolism (26,066 cases and 624,053 controls) and meta-analyzed both studies, followed by independent replication with up to 17,672 venous thromboembolism cases and 167,295 controls. We identified 22 previously unknown loci, bringing the total number of venous thromboembolism-associated loci to 33, and subsequently fine-mapped these associations. We developed a genome-wide polygenic risk score for venous thromboembolism that identifies 5% of the population at an equivalent incident venous thromboembolism risk to carriers of the established factor V Leiden p.R506Q and prothrombin G20210A mutations. Our data provide mechanistic insights into the genetic epidemiology of venous thromboembolism and suggest a greater overlap among venous and arterial cardiovascular disease than previously thought.